## <u>REC¤VERY</u>

## Randomised Evaluation of COVID-19 Therapy Sample Form (v16.00 - 28/07/21)

## **Randomisation Program**

Call Freefone 0800 138 5451 to contact the RECOVERY team for URGENT problems using the Randomisation Program or for medical advice. All NON-URGENT queries should be emailed to recoverytrial@ndph.ox.ac.uk

	Logged in a	s: RECOVERY Site
	Section A: Bas	eline and Eligibility
	Date and time of rand	omisation: 27 Jul 2021 14:00
Treating clinician A1. Name of treating clinician		
Patient details		
A2. Patient surname		
Patient forename A3. National ID	Tick if not available	
A4. What is the patient's Nepali date of birth?		
A4. What is the patient's repail date of birth?	v/v/v/v	
A5. What is the patient's date of birth?		
Inclusion criteria		
A6. Has consent been taken in line with the protocol? If answer is No patient cannot be enrolled in the study	<b>`</b>	
A6.0 How was consent obtained?	~	
A7. Does the patient have proven or suspected SARS-CoV- 2 infection? If answer is No patient cannot be enrolled in the study	<b>v</b>	
A8. Does the patient have any medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial?	<b>v</b>	
A9. COVID-19 symptom onset date:	<b>v</b> / <b>v</b> / <b>v</b>	
A10. Date of hospitalisation:	<b>v</b> / <b>v</b> / <b>v</b>	
A11. Does the patient require oxygen?	<b>~</b>	
A12. Please select one of the following to describe the current level of ventilation support	~	
A12.1 Enter latest oxygen saturation measurement (%)		
A12.2 Enter latest CRP measurement since admission to hospital (mg/L) Enter 0 if below the limit of measurement	Tick if not measured     Tick if greater than limit of measurement	
A12.3 Enter latest creatinine measurement since admission to hospital Please select correct units for the measurement (mg/dL or µmol/L).	mg/dL v Tick if not measured	
A12.4 Enter latest D-dimer measurement since admission to hospital Please select correct units for the measurement (mg/L or ng/mL). Enter 0 if below the limit of measurement	Tick if greater than limit of measurement	
A12.5 Has the patient received a COVID-19 vaccine?	<b>``</b>	
Does the patient have any CURRENT comorbidities or A13.1 Diabetes		
A13.2 Heart disease	✓	
A13.3 Chronic lung disease	· ·	
A13.4 Tuberculosis	<b>v</b>	
A13.5 HIV		
A13.6 Severe liver disease	✓	
A13.7 Severe kidney impairment (eGFR<30 or on dialysis)	×	
A13.7.1 Is the patient on dialysis or haemofiltration?	<b>`</b>	
A13.8 Known long QT syndrome	<b>`</b>	
A13.9 Current treatment with macrolide antibiotics which are to continue Macrolide antibiotics include clarithromycin, azithromycin and enythromycin	<b></b>	
A13.10 Antiplatelet therapy Includes aspirin, clopidogrel, ticagrelor, prasugrel, dipyridamole	<b>``</b>	
A13.12 Has received tocilizumab therapy during this admission	<b>`</b>	
Are the following treatments UNSUITABLE for the p If you answer Yes it means you think this patient sho	atient? uld NOT receive this drug.	
A14E.1 High-dose corticosteroids	v	
A14F.1 Empagliflozin Empagliflozin is NOT suitable if patient (i) has type 1 diabetes mellitus; or (ii) is pregnant or breastfeeding	<b>v</b>	
Are the following treatments available? A15E.1 High-dose corticosteroids	<b>v</b>	
A15F.1 Empagliflozin Current medication		
A16.1 Is the patient currently prescribed remdesivir?	<b>v</b>	
A16.2 Is the patient currently prescribed systemic corticosteroids (dexamethasone, prednisolone, hydrocortisone, methylprednisolone)? Please do not include bojical or inhaled treatments	<b>``</b>	
A16.4 Is the patient currently on warfarin or a direct oral anticoagulant? Includes apixaban, rivaroxaban	<b>`</b>	
A16.5 What venous thromboembolism prophylaxis is the patient receiving? Standard = usual for hospitalised patients (not increased due to COVID-19); Higher dose = treatment dose or increased prophylaxis due to COVID-19	<b>`</b>	
Please sign off this form once complete Surname:		
Forename:		
Professional email:		
	Continue	